A Study of QL1706H in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Advanced Solid Tumors

Interventions

DRUG

QL1706H

QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06047431 - A Study of QL1706H in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter